hyperuricemia and tophaceous gout Archives

Abstract Number: 209 • ACR/ARHP Annual Meeting 2016
Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Thomas Bardin¹, Nicola Dalbeth², Robert Terkeltaub³, Chris Storgard⁴, Maple Fung⁴, Jia Hu⁴ and Fernando Perez-Ruiz⁵, ¹Hôpital Lariboisière, Paris, France, ²University of Auckland, Auckland, New Zealand, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Hospital de Cruces and Biocruces Health Research Institute, Vizcaya, Spain
Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…
Abstract Number: 219 • ACR/ARHP Annual Meeting 2016
Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
Nicola Dalbeth¹, Savvas Nicolaou², Scott Baumgartner³, Jia Hu³, Maple Fung³ and Hyon K. Choi⁴, ¹University of Auckland, Auckland, New Zealand, ²Radiology, University of British Columbia, Vancouver, BC, Canada, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic hyperuricemia predisposes to deposition of monosodium urate (MSU) crystals in musculoskeletal and other tissues, causing chronic inflammation, acute gout flares, joint damage, and…
Abstract Number: 226 • ACR/ARHP Annual Meeting 2016
Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA
Puja Khanna¹, Eskinder Tafesse², Scott Baumgartner³, Anna Walker⁴ and Robert Morlock³, ¹Rheumatology, University of Michigan, Ann Arbor, MI, ²AstraZeneca Pharmaceuticals, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA, ⁴AstraZeneca Pharmaceuticals, Luton, United Kingdom
Background/Purpose: Less than 30% of gout patients achieve treatment targets and patients with tophi are less likely to achieve these goals than patients without tophi.…
Abstract Number: 2354 • ACR/ARHP Annual Meeting 2015
The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Robert Terkeltaub¹, Fernando Perez-Ruiz^2,3,4, Jeff Kopicko⁵, Maple Fung⁵, Scott Adler⁶, Chris Storgard⁷, Scott Baumgartner⁵ and Nicola Dalbeth⁸, ¹Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ²Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, ³BioCruces Health Research Institute, Baracaldo, Spain, ⁴Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Previous studies have shown that long-term urate-lowering therapy (ULT) is required for improvements in gout flare frequency and tophi reduction, and that lower serum…

Abstracts tagged "hyperuricemia and tophaceous gout"

Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout

Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol

Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA

The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors